Understanding and Managing Hemophilia with Personalized Care | Prime Therapeutics - Prime Therapeutics
Support your members with hemophilia
Learn more about hemophilia
Hemophilia is a rare bleeding disorder that happens when the blood does not clot normally due to missing or low levels of proteins known as clotting factors. This is an X-linked recessive disorder. This means both parents need to be carriers for their child to have hemophilia. Women are most often carriers, and hemophilia occurs much more frequently in men than in women. Hemophilia occurs in about 1 in 5,600 live male births, and between 30,000–33,000 men in United States have hemophilia.1
14
Hemophilia is the 14th most expensive drug category based on Prime’s combined commercial medical and pharmacy claims data.2
See how Prime can help
Advances in treatment have improved quality and length of life for those with hemophilia, but hemophilia factor prophylaxis treatment can be costly — frequently more than $600,000 per year.3 As with drugs for many chronic conditions, members can find it challenging to follow treatment plans. They may also face a lack of individualized treatment and fragmentation of care between treatment centers and pharmacies. That’s where Prime comes in, delivering:
Proactive education
Prime educates providers, pharmacies and hemophilia patient advocacy groups on your program policies and goals before we implement our hemophilia solutions.
Quality assurance
We use your data to determine utilization patterns, outlier members, treatment facilities, prescribing habits and cost compared to national and regional benchmarks.
Clinical rigor
Manage your benefits and data through our utilization management (UM) reviews, which provide key clinical info and optimize factor dosing in line with pharmacokinetic (PK) testing.
Choose what works best for you and your members
Footnotes
*All brand names are property of their respective owners.
**The programs listed are not available to all clients. Please check with your representative if you are interested in learning more.
1 Soucie, J. M., Miller, C. H., Dupervil, B., Le, B., & Buckner, T. W. (2020). Occurrence rates of haemophilia among males in the United States based on surveillance conducted in specialized haemophilia treatment centres. Haemophilia, 26(3), 487–493. https://doi.org/10.1111/hae.13998
2 Internal analysis, 2024
3 Patient Out-of-Pocket Expenses. (n.d.). National Bleeding Disorders Foundation. https://www.bleeding.org/advocacy/state-priorities/patient-out-of-pocket-expenses
4 Internal analysis, 2017-2024